IHS Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Demonstrate the potential of pharmaceuticals, biotechnology products, medical devices and care delivery patterns on patient health outcomes, medical costs, productivity and quality of life
Identify and quantify key cost drivers to develop efficient, evidence-based estimates for reimbursement and prospective payment
Healthcare Pricing Models
Develop the optimal new drug price and market entry strategy
Market Entry Analysis
Receive continuous analysis, data and online tools covering technology, reimbursement, regulations, geographic/therapeutic segment scenarios
Partner with us for customized research on business improvement and opportunity maximization strategies
Access customized research at less cost by participating in multi-client, syndicated market research that employs qualitative and quantitative surveys, market access scenarios and market analysis
Integrating HTA Requirements into Oncology R&D Process
A pharmaceutical company needed recommendations for incorporating more HTA considerations into R&D decision-making.
We researched recent HTA decisions in Australia, US, United Kingdom, France, Germany, Italy and Spain in the client’s four therapeutic areas. Our detailed case studies identified the choice of trial design, trial comparator, patient group selection, primary and secondary outcome measures, strength of correlation between surrogate and final outcomes, traits of PRO evidence and studies, and a definition of clinical relevance.
We helped the client build user-friendly HTA "checklists". The client uses these checklists to ensure its R&D personnel factor HTA considerations into future planning.
Millions of lives are saved by blood transfusions and this company plays a vital role in making transfusions safe. To provide hospitals with the best pre-transfusion diagnostic products, its researchers are identifying next-generation concepts and generating important innovations while also resolving problems and documenting their findings more efficiently.
A top manufacturer of medical supplies reduced commodity costs by millions of dollars within 18-20 months and enabled its team to negotiate better rates – e.g., pushing back on 6 commodity cost increases in 8 months due to more accurate pricing data. Enabling tighter forecasts and improving workflows helps the company serve consumers more effectively.
What's next for pharmaceutical M&A activity? http://t.co/QItRXKDcho
Sustainability of Colombian healthcare reform http://t.co/zpuhqrWTxi
Polish pharma industry furious over MoH’s “warning” to HTA agency http://t.co/CT6S9fnCiW
Repatha versus Praluent: Will the approval of PCSK9 inhibitors trigger a new price war in the US? http://t.co/jMuc26Xg4H
Follow Life Sciences Consulting @IHS4LifeScience